Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02ALK
|
||||
| Former ID |
DNC005716
|
||||
| Drug Name |
6-Pyridin-3-yl-naphthalen-2-ol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [527801] | ||
| Formula |
C15H11NO
|
||||
| Canonical SMILES |
C1=CC(=CN=C1)C2=CC3=C(C=C2)C=C(C=C3)O
|
||||
| InChI |
1S/C15H11NO/c17-15-6-5-11-8-12(3-4-13(11)9-15)14-2-1-7-16-10-14/h1-10,17H
|
||||
| InChIKey |
MDXMZUQFVFTPDO-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cytochrome P450 11B1, mitochondrial | Target Info | Inhibitor | [527801] | |
| 17 alpha-hydroxylase-C17, 20-lyase | Target Info | Inhibitor | [527801] | ||
| PathWhiz Pathway | SteroidogenesisPW000045:Androgen and Estrogen Metabolism | ||||
| Steroidogenesis | |||||
| WikiPathways | Metapathway biotransformation | ||||
| Oxidation by Cytochrome P450 | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| Corticotropin-releasing hormoneWP702:Metapathway biotransformation | |||||
| Steroid Biosynthesis | |||||
| Glucocorticoid & Mineralcorticoid Metabolism | |||||
| Prostate Cancer | |||||
| Phase 1 - Functionalization of compounds | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.